2 weeks Ago By Defense World Staff
BTIG Research restated their neutral rating on shares of Poseida Therapeutics ( NASDAQ:PSTX – Free Report ) in a research note published on Tuesday morning, Benzinga reports. A number of other analysts also recently weighed in on PSTX. William Blair restated a “market perform” rating on shares of Poseida Therapeutics in a report on Tuesday.
HC Wainwright reissued a “neutral” rating and set a $9.00 price objective (down from $20.00) on shares of Poseida Therapeutics in a research note on Tuesday.
Get Our Latest Stock Analysis on Poseida Therapeutics Poseida Therapeutics Trading Up 228.0 % Institutional Investors Weigh In On Poseida Therapeutics Several institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC grew its holdings in Poseida Therapeutics by 53.
4% during the 2nd quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock valued at $2,496,000 after purchasing an additional 297,500 shares during the last quarter. Vanguard Group Inc.
grew its stake in shares of Poseida Therapeutics by 16.3% during the first quarter. Vanguard Group Inc.
now owns 3,373,065 shares of the company’s stock valued at $10,760,000 after buying an additional 473,746 shares during the last quarter. Public Employees Retirement System of Ohio raised its holdings in shares of Poseida Therapeutics by 177.3% in the first quarter.
Public Employees Retirement System of Ohio now owns 62,945 shares of the company’s stock worth $201,000 after buying an additional 40,245 shares during the period. Lazard Asset Management LLC lifted its stake in shares of Poseida Therapeutics by 280.3% during the 1st quarter.
Lazard Asset Management LLC now owns 28,679 shares of the company’s stock worth $91,000 after acquiring an additional 21,138 shares during the last quarter. Finally, Bayesian Capital Management LP purchased a new position in Poseida Therapeutics during the 1st quarter valued at $33,000. Institutional investors own 46.
87% of the company’s stock. About Poseida Therapeutics ( Get Free Report ) Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.
Read More Five stocks we like better than Poseida Therapeutics Pros And Cons Of Monthly Dividend Stocks Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor 3 Warren Buffett Stocks to Buy Now Why Warren Buffett Is Selling: A Look at His Latest Market Moves Stock Average Calculator Why Amazon Shares May Never Trade Below $200 Again Receive News & Ratings for Poseida Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poseida Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
